# The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases

> **NCT03711240** · PHASE2 · UNKNOWN · sponsor: **National Cheng-Kung University Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT03711240
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-08
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03711240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03711240, "The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03711240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*